Takeda Pharmaceutical Company Limited
TAK
$17.63
$0.241.38%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 29.67B | 29.79B | 29.85B | 29.62B | 29.99B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.67B | 29.79B | 29.85B | 29.62B | 29.99B |
| Cost of Revenue | 10.53B | 10.68B | 10.29B | 10.42B | 10.50B |
| Gross Profit | 19.14B | 19.11B | 19.56B | 19.20B | 19.49B |
| SG&A Expenses | 7.15B | 7.15B | 7.27B | 7.21B | 7.29B |
| Depreciation & Amortization | 3.08B | 3.32B | 3.57B | 3.56B | 3.61B |
| Other Operating Expenses | 471.11M | 308.29M | 151.76M | 635.12M | 227.68M |
| Total Operating Expenses | 25.67B | 25.87B | 25.92B | 26.45B | 26.34B |
| Operating Income | 3.99B | 3.92B | 3.93B | 3.17B | 3.65B |
| Income Before Tax | -783.23M | -745.71M | 1.40B | 703.04M | 1.32B |
| Income Tax Expenses | 229.53M | 106.36M | 620.97M | 442.33M | 355.19M |
| Earnings from Continuing Operations | -1.01K | -852.07 | 777.52 | 260.71 | 959.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.86M | -1.74M | -1.72M | -1.41M | -1.34M |
| Net Income | -1.01B | -853.81M | 775.80M | 259.30M | 958.61M |
| EBIT | 3.99B | 3.92B | 3.93B | 3.17B | 3.65B |
| EBITDA | 7.94B | 8.12B | 8.33B | 7.56B | 8.08B |
| EPS Basic | -0.64 | -0.53 | 0.50 | 0.17 | 0.61 |
| Normalized Basic EPS | 1.21 | 1.19 | 1.31 | 0.89 | 1.07 |
| EPS Diluted | -0.66 | -0.55 | 0.48 | 0.16 | 0.60 |
| Normalized Diluted EPS | 1.20 | 1.18 | 1.30 | 0.89 | 1.05 |
| Average Basic Shares Outstanding | 6.32B | 6.30B | 6.30B | 6.31B | 6.31B |
| Average Diluted Shares Outstanding | 6.37B | 6.35B | 6.35B | 6.33B | 6.36B |
| Dividend Per Share | 1.30 | 1.30 | 1.32 | 1.32 | 1.30 |
| Payout Ratio | -198.03% | -244.50% | 270.24% | 803.40% | 217.56% |